Veru(NASDAQ) VERU

Veru develops medicines for cancer and related conditions. Its products aim to help patients manage disease symptoms and treatment side effects. The company’s work targets people with cancer and those at risk of muscle loss or cardiovascular disease.

What’s in the Medicine Cabinet? (Products & Services)

• Enobosarm (0% of current revenue): Oral drug in late-stage trials for muscle loss in obesity and certain breast cancers; targets older adults and cancer patients.
• Sabizabulin (0% of current revenue): Oral therapy in trials for breast and prostate cancers, and COVID-19 complications; aimed at patients with advanced disease.
• Combination Therapies (0% of current revenue): Enobosarm with abemaciclib, and sabizabulin with enobosarm, both in trials for difficult-to-treat breast cancers.
• VERU-100 (0% of current revenue): Injectable drug in trials for advanced prostate cancer; targets men with hormone-sensitive disease.
• Zuclomiphene Citrate (0% of current revenue): Oral therapy in trials for hot flashes; intended for people experiencing menopause symptoms.
• Former Commercial Products (100% of revenue until December 2024): FC2 female/internal condom, sold to health agencies and nonprofits; business sold in December 2024.

Growth Spurts and Strategic Shifts

• Sold FC2 condom business to Clear Future in December 2024, exiting commercial sales.
• Sold ENTADFI assets to Onconetix in April 2023, focusing on drug development.
• Advanced enobosarm into a Phase 2b trial for muscle loss in 2024-2025 and is planning a Phase 3 clinical program.
• Completed a new oral formulation of enobosarm, with a Phase 1 trial in July 2025.
• Initiated regulatory discussions with the FDA for enobosarm’s next trial phase in 2025.

Why Veru Stands Out (Without the Lab Coat)

Veru shifted from selling products to focusing on drug development. It controls its clinical data and patents, including a new oral drug formulation. The company targets gaps in cancer and obesity care with late-stage clinical trials.

Five Things You Need to Know

• Revenue was $0 in QQ1 2026, down 100% from $2 million in QQ1 2024.
• Net loss was $7.3 million for the quarter ended June 30, 2025.
• Cash position was $15 million as of June 30, 2025, down from $24.9 million in September 2024.
• 210 full-time employees as of the latest report; company operations are focused on late-stage drug development.
• Substantial doubt exists about the company’s ability to continue as a going concern.

Bottom Line

Veru has transformed from a product seller to a clinical-stage drug developer. Its future depends on advancing new medicines for cancer and related diseases.